Data from the Phase 3 RAY (MCL3001) study, an investigational clinical trial, showed oral IMBRUVICA® (ibrutinib) significantly improved progression-free survival (PFS; the primary endpoint)...

TopBuild Corp. (NYSE: BLD), the leading installer and distributor of insulation products to the United States construction industry, announced that Robert Buck, President and Chief Operating...

Digital Turbine, Inc. (Nasdaq: APPS), the company empowering operators and Original Equipment Manufacturers (OEMs) around the globe with end-to-end mobile solutions, today announced that...

Salesforce (NYSE: CRM), the Customer Success Platform and world's #1 CRM company, today announced that Salesforce executives will participate in the following investor events: Tuesday, Dec. 8,...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and...

Imago BioSciences, Inc., a biotech company developing innovative therapeutics for myeloid diseases, today announced a presentation at the 57th ASH Annual Meeting this week in Orlando, Florida. The...

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced the presentation of data from its ZFP Therapeutic programs, including data demonstrating the...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m....

DuPont Fabros Technology, Inc. (NYSE: DFT), a leading owner, developer, operator and manager of enterprise-class, carrier-neutral, large multi-tenant wholesale data centers, today announced that...

Paragon Offshore plc ("Paragon") (NYSE: PGN) announced today that Lee M. Ahlstrom, Senior Vice President – Investor Relations, Strategy and Planning of Paragon, will present at the Capital One...

Klas Telecom demonstrated a strong multipresence at this year's largest-ever U.S. Army Network Integration Evaluation (NIE) 16.1, where the company's products and services supported three...

The 2016 Expo Light Shanghai will be an important theme at the Shanghai Hospitality Design & Engineering Exposition, which will be held at the Shanghai New International Expo Center from March 29...

Value investment firm Brandes Investment Partners, L.P., announced today that Charles Brandes, CFA, will present at the inaugural Asia Value Investor Conference in Hong Kong on December 8, 2015....

Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®)...

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral...

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory...

Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy...

Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA®) significantly...

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition represent a...

Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART) therapy CTL019 in certain types of relapsed or refractory...

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced results from a new analysis of the pivotal Phase 3 trial, PERSIST-1,...

Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in...

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health...

WHO: Andre Goy, M.D., M.S., Chairman, John Theurer Cancer Center and Chief, Division of Lymphoma, Hackensack University Medical Center; Andrew L. Pecora, MD, FACP, CPE, Vice President of Cancer...

CME Group announced today that John Pietrowicz, Chief Financial Officer, and Sean Tully, Senior Managing Director, Financial and OTC Products, will present at the Goldman Sachs U.S. Financial...